A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
Sun Yat-sen University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sichuan Baili Pharmaceutical Co., Ltd.
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
M.D. Anderson Cancer Center
All India Institute of Medical Sciences
Canadian Cancer Trials Group
Canadian Cancer Trials Group
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Sun Yat-sen University
AVEO Pharmaceuticals, Inc.
Alliance for Clinical Trials in Oncology
PDS Biotechnology Corp.
Sun Yat-sen University
NRG Oncology
Fudan University
Groupe Oncologie Radiotherapie Tete et Cou
Mayo Clinic
West China Hospital
Merus B.V.
Gustave Roussy, Cancer Campus, Grand Paris
Merck Sharp & Dohme LLC